Published in J Neurol Neurosurg Psychiatry on April 01, 1996
Paraneoplastic syndromes of the CNS. Lancet Neurol (2008) 4.62
Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry (1999) 1.77
Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry (2000) 1.59
Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol (2004) 1.29
Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol (2014) 1.25
Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry (2002) 1.13
Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry. Oncoimmunology (2013) 0.99
Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol (2009) 0.92
Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. J Neuroinflammation (2014) 0.90
Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry (1997) 0.83
Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome. Clin Exp Immunol (2014) 0.82
Long-term efficiency of intravenously administered immunoglobulin in anti-Yo syndrome with paraneoplastic cerebellar degeneration. J Neurol (2010) 0.80
Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes. J Neurol (2006) 0.80
Progress in the management of paraneoplastic neurological disorders. Ther Adv Neurol Disord (2010) 0.80
Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction. Gastroenterol Hepatol (N Y) (2013) 0.78
Intravenous immunoglobulins in paraneoplastic brainstem encephalitis with anti-Ri antibodies. J Neurol (2006) 0.78
Paraneoplastic neurological complications of breast cancer. Exp Hematol Oncol (2016) 0.78
A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neuro Oncol (2014) 0.77
Paraneoplastic Diseases of the Nervous System. Curr Treat Options Neurol (1999) 0.76
Myasthenia gravis-like syndrome presenting as a component of the paraneoplastic syndrome of lung adenocarcinoma in a nonsmoker. Case Rep Oncol Med (2014) 0.75
Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System. Front Immunol (2017) 0.75
7th International Immunoglobulin Conference: Interlaken Leadership Awards. Clin Exp Immunol (2014) 0.75
The Production Processes and Biological Effects of Intravenous Immunoglobulin. Biomolecules (2016) 0.75
Intravenous immunoglobulin treatment in chronic neurological diseases: do we have maintenance dose right? Autoimmune Dis (2014) 0.75
Paraneoplastic cerebellar degeneration in Hodgkin's lymphoma. Ann Indian Acad Neurol (2012) 0.75
Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer. BMC Cancer (2015) 0.75
CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model. Oncoimmunology (2016) 0.75
Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) (1992) 3.21
Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology (1992) 3.11
High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology (1990) 3.05
High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology (1990) 1.69
Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci (1985) 1.67
Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology (1988) 1.66
Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry (1993) 1.33
Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology (1994) 1.32
Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry (1993) 1.28
Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology (1994) 1.20
Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve (1994) 1.17
Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology (1994) 1.09
Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol (1991) 1.06
Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA (1987) 1.06
High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology (1989) 1.03
Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology (1994) 1.00
Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol (1992) 0.92
Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical-immunologic correlation. Neurology (1994) 0.91
Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin. Pediatr Res (1993) 0.90
[Autoimmunity and paraneoplastic neurologic syndromes]. Rev Neurol (Paris) (1991) 0.89
[Paraneoplastic cerebellar degeneration]. Rev Neurol (Paris) (1994) 0.87
Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol (1994) 0.84
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (2004) 10.58
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain (2001) 5.04
Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) (1992) 3.21
Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol (2010) 2.77
Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain (1997) 2.64
Radiation-induced dementia in patients cured of brain metastases. Neurology (1989) 2.59
Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med (1990) 2.54
Cerebrovascular complications in patients with cancer. Medicine (Baltimore) (1985) 2.39
Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain (2001) 2.34
Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol (2001) 2.24
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol (1997) 2.19
Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J (1993) 2.18
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology (2000) 2.17
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (2005) 2.09
Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol (2003) 2.01
SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology (2007) 2.00
Analysis of relapses in anti-NMDAR encephalitis. Neurology (2011) 1.98
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol (2004) 1.97
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol (1999) 1.91
Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol (2001) 1.90
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86
Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology (1997) 1.85
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol (2010) 1.85
Motor neuron syndromes in cancer patients. Ann Neurol (1997) 1.82
Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology (2004) 1.81
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79
Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology (2003) 1.79
Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology (2004) 1.77
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology (1996) 1.74
Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain (1997) 1.73
GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology (2011) 1.71
Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol (2006) 1.67
Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology (1988) 1.66
Mouse IL-17: a cytokine preferentially expressed by alpha beta TCR + CD4-CD8-T cells. J Interferon Cytokine Res (1996) 1.65
Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol (2012) 1.62
Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry (2000) 1.59
Neurological complications of radiotherapy and chemotherapy. J Neurol (1998) 1.56
Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol (2009) 1.52
Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia (2010) 1.51
Cyclosporine-associated mutism in liver transplant patients. Neurology (1996) 1.49
Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology (2009) 1.48
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol (2001) 1.47
Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology (1992) 1.47
Brainstem gliomas in adults: prognostic factors and classification. Brain (2001) 1.46
Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol (1985) 1.46
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol (1989) 1.45
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology (2008) 1.44
ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene (2011) 1.42
[Spinal cord compression in cancer patients]. Med Clin (Barc) (1997) 1.39
Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. Neurology (1998) 1.39
[Chronic meningitis before diagnosis of celiac disease]. Rev Neurol (Paris) (2002) 1.39
Partial characterization of the Purkinje cell antigens in paraneoplastic cerebellar degeneration. Neurology (1986) 1.39
Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res (1999) 1.38
[Allergology in the public health service of the Community of Madrid: current situation and opportunities in the XXI century public health system]. An Sist Sanit Navar (2015) 1.37
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36
Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine (Baltimore) (1988) 1.35
Neurological complications of primary Sjögren's syndrome. J Neurol (2001) 1.34
Initial chemotherapy in gliomatosis cerebri. Neurology (2004) 1.33
Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology (2000) 1.28
Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res (2000) 1.27
Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology (1991) 1.26
Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis. J Immunol (2001) 1.24
Central nervous system involvement in mantle cell lymphoma. Ann Oncol (2007) 1.22
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry (2008) 1.22
Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia (2010) 1.22
Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology (1994) 1.20
Spectrum of paraneoplastic disease associated with lymphoma. Neurology (2011) 1.20
OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet (2001) 1.19
Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg (1995) 1.18
Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J Neurol Neurosurg Psychiatry (2006) 1.18
EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol (2006) 1.17
Hypersensitivity to latex, chestnut, and banana. Ann Allergy (1993) 1.16
Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Rheum (1986) 1.15
Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology (2004) 1.14
Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol (1999) 1.11
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol (2002) 1.10
Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology (2009) 1.09
Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer (1999) 1.09
Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology (1993) 1.08
Neuronal antinuclear antibody (anti-Hu) in paraneoplastic encephalomyelitis simulating acute polyneuritis. Acta Neurol Scand (1987) 1.07
CNS involvement in mantle-cell lymphoma. J Clin Oncol (1996) 1.05
Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor. EMBO J (1993) 1.04
Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology (2007) 1.03
Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry (1999) 1.03